Literature DB >> 12165495

Role of B7 costimulatory molecules in the adjuvant activity of the heat-labile enterotoxin of Escherichia coli.

Michael Martin1, Arlene Sharpe, John D Clements, Suzanne M Michalek.   

Abstract

Much interest has been directed at understanding the adjuvant properties of the heat-labile enterotoxin of Escherichia coli (LT). In this study, we have assessed how LT compared with the nonenzymatic mutant LT (E112K) affect the level of B7-1 and B7-2 expression on APCs, and we determined how these costimulatory molecules influence their adjuvant properties. Analysis of B7-1 and B7-2 expression on B cells revealed that LT enhanced B7-2 but not B7-1, while LT (E112K) had no effect on the expression of either costimulatory molecule. Treatment of macrophage or dendritic cells with LT resulted in a predominant enhancement of B7-2, while LT (E112K) induced mainly B7-1 expression. Analysis of LT- and LT (E112K)-treated B cells, macrophage, and dendritic cells also revealed significant differences in their ability to enhance anti-CD3-stimulated CD4(+) T cell proliferative responses via B7-1 and B7-2. Furthermore, the ability of LT to enhance both Ab and CD4(+) T cell responses to a coadministered Ag was severely abrogated in B7-2- but not B7-1-deficient mice. In contrast, the in vivo adjuvant properties of LT (E112K) appeared to be mediated by both B7-1 and B7-2 for optimal CD4(+) T cell responses, while B7-1 appeared to be the predominant B7 molecule involved in the ability of LT (E112K) to augment Ab responses to a coadministered Ag. These findings demonstrate distinct differences in the ability of LT and LT (E112K) to enhance B7-1 and B7-2 on APC, as well as a dependence upon these costimulatory molecules for their adjuvant properties.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12165495     DOI: 10.4049/jimmunol.169.4.1744

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Enhancing DNA vaccine potency by modifying the properties of antigen-presenting cells.

Authors:  Shaw-Wei D Tsen; Augustine H Paik; Chien-Fu Hung; T-C Wu
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

2.  Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens.

Authors:  Sabena Uddowla; Lucy C Freytag; John D Clements
Journal:  Vaccine       Date:  2007-10-02       Impact factor: 3.641

3.  Cellular mechanisms of the adjuvant activity of the flagellin component FljB of Salmonella enterica Serovar Typhimurium to potentiate mucosal and systemic responses.

Authors:  Oscar Pino; Michael Martin; Suzanne M Michalek
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

4.  Role of Toll-like receptors in host responses to a virulence antigen of Streptococcus mutans expressed by a recombinant, attenuated Salmonella vector vaccine.

Authors:  Mohammad Abdus Salam; Jannet Katz; Suzanne M Michalek
Journal:  Vaccine       Date:  2010-07-12       Impact factor: 3.641

5.  The role of glycogen synthase kinase 3 in regulating IFN-β-mediated IL-10 production.

Authors:  Huizhi Wang; Jonathan Brown; Carlos A Garcia; Yunan Tang; Manjunatha R Benakanakere; Terrance Greenway; Pascale Alard; Denis F Kinane; Michael Martin
Journal:  J Immunol       Date:  2010-12-15       Impact factor: 5.422

6.  The Mycoplasma-derived macrophage-activating 2-kilodalton lipopeptide triggers global immune activation on nasal mucosa-associated lymphoid tissues.

Authors:  Faiza Rharbaoui; Astrid Westendorf; Claudia Link; Sandra Felk; Jan Buer; Matthias Gunzer; Carlos A Guzmán
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

7.  Role of B7 costimulatory molecules in mediating systemic and mucosal antibody responses to attenuated Salmonella enterica serovar Typhimurium and its cloned antigen.

Authors:  Carlos A Garcia; Michael Martin; Suzanne M Michalek
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

8.  Probing local innate immune responses after mucosal immunisation.

Authors:  Lindsay J Hall; Simon Clare; Gordon Dougan
Journal:  J Immune Based Ther Vaccines       Date:  2010-09-13

9.  Role of CD80 and CD86 in host immune responses to the recombinant hemagglutinin domain of Porphyromonas gingivalis gingipain and in the adjuvanticity of cholera toxin B and monophosphoryl lipid A.

Authors:  Ping Zhang; Janina P Lewis; Suzanne M Michalek; Jannet Katz
Journal:  Vaccine       Date:  2007-06-19       Impact factor: 3.641

10.  Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants.

Authors:  Hesham F Nawar; Sergio Arce; Michael W Russell; Terry D Connell
Journal:  Infect Immun       Date:  2006-11-21       Impact factor: 3.441

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.